stockrow
Saturday 7 November 2026
Export OCUL’s income statement to Excel — free account
Ocular Therapeutix, Inc.
OCUL Healthcare Biotechnology
Ocular Therapeutix, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.0 million, down 18.5% from fiscal 2024.
- Revenue
- +0.12%
- EPS
- +10.3%
- Free cash flow
- −25.4%
- Total debt
- +4.13%
Quarter to June 2026, against a year earlier
6.62
0.19
+2.95%
Follow OCUL
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
38.54 | 43.75 | 36.48 | 42.44 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(42.39) | (41.90) | (28.76) | (32.84) | |
P/B ratio |
8.33 | 3.47 | 3.26 | 4.25 | |
Price to Tangible BV |
8.33 | 3.47 | 3.26 | 4.25 | |
EV/Sales |
33.63 | 30.94 | 25.05 | 32.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.87) | (7.85) | (5.76) | (7.07) | |
EV/FCF |
(9.41) | (7.42) | (5.41) | (6.60) | |
Quick Ratio |
7.62 | 15.11 | 14.49 | 12.79 | |
Current Ratio |
7.85 | 15.39 | 14.81 | 13.11 | |
Net Debt/EBITDA |
4.05 | 9.72 | 6.46 | 6.55 | |
Debt/Assets |
17.19% | 8.83% | 9.84% | 10.84% | |
Debt/Equity |
0.27 | 0.11 | 0.12 | 0.14 | |
Asset Turnover |
0.12 | 0.08 | 0.09 | 0.09 | |
Operating CF/Net income |
0.73 | 0.84 | 0.74 | 0.85 | |
Capex/Depreciation |
(5.61) | (2.28) | (3.63) | (1.82) | |
Interest Coverage |
(22.88) | (24.62) | (33.61) | (29.41) | |
Research and Development Expense of Revenue |
360.00% | 383.40% | 613.94% | 401.77% | |
Selling, General and Administrative Expense of Revenue |
200.15% | 231.07% | 339.20% | 292.65% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
80.38% | 85.73% | 144.48% | 108.71% | |
Graham Net Nets |
0.11 | 0.28 | 0.29 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.32%) | (11.86%) | (17.24%) | (14.46%) | |
Free Cash Flow Yield |
(9.27%) | (9.54%) | (12.69%) | (11.55%) | |
Revenue per Share |
0.08 | 0.07 | 0.05 | 0.06 | |
Operating CF per Share |
(0.28) | (0.29) | (0.29) | (0.30) | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.01) | |
Free Cash Flow per Share |
(0.31) | (0.30) | (0.32) | (0.31) | |
Cash per Share |
1.87 | 3.94 | 2.98 | 2.66 | |
Shareholders Equity per Share |
1.40 | 3.49 | 2.60 | 2.31 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.40 | 3.49 | 2.60 | 2.31 | |
Free Cash Flow |
(56.72) | (57.09) | (70.65) | (70.64) | |
Working Capital |
337.69 | 731.32 | 658.31 | 595.25 | |
Capital Expenditures |
(5.99) | (2.84) | (4.66) | (3.37) | |
Net Current Asset Value |
234.33 | 628.38 | 555.04 | 493.15 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.41 | 0.21 | 0.43 | 0.25 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
30.50 | 31.52 | 24.78 | 30.34 | |
Average Payables |
5.13 | 4.17 | 6.33 | 6.44 | |
Average Inventory |
2.95 | 3.30 | 3.50 | 3.43 | |
Average Assets |
450.63 | 633.00 | 569.22 | 561.33 | |
Average Common Equity |
305.13 | 484.83 | 423.75 | 412.98 |
Columns are period end dates